TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23266575

Group type: EXPERIMENTAL
Intervention: 2-COM communication tool
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 0
Study: 22928779

Group type: EXPERIMENTAL
Intervention: 2v2 small-sided games
Number of subjects: 16

Group type: COMPARATOR
Intervention: 4v4 small-sided games
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Full court games
Number of subjects: 16

Group type: COMPARATOR
Intervention: Half court games
Number of subjects: 16
Study: 20116961

Group type: EXPERIMENTAL
Intervention: Engaging Moms Program (EMP)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Intensive Case Management Services (ICMS)
Number of subjects: 62
Study: 18329261

Group type: EXPERIMENTAL
Intervention: Fatty fish or long-chain n-3 PUFA intake higher than 0.10% of energy intake
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fatty fish intake
Number of subjects: 0
Study: 16306858

Group type: EXPERIMENTAL
Intervention: THC (10 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Cannabis extract (10 mg THC + 5.4 mg CBD)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 16221650

Group type: EXPERIMENTAL
Intervention: Group therapy
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control group (no group therapy)
Number of subjects: 13
Study: 9140674

Group type: EXPERIMENTAL
Intervention: Nicardipine SR (40‐80 mg for 21 months)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Alacepril (25‐100 mg for 18 months)
Number of subjects: 20
Study: 2626193

Group type: EXPERIMENTAL
Intervention: S-adenosyl-L-methionine
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 180198

Group type: EXPERIMENTAL
Intervention: Adenine arabinoside for five days
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study: 30685685

Group type: EXPERIMENTAL
Intervention: Three-drug combination chemotherapy with methotrexate, doxorubicin, and cisplatin (standard chemotherapy)
Number of subjects: 2260
Study: 29229055

Group type: EXPERIMENTAL
Intervention: Upper cervical translatoric spinal mobilization (UC‐TSM)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 82
Study: 25851756

Group type: EXPERIMENTAL
Intervention: Weekly azathioprine 300 mg pulse
Number of subjects: 60

Group type: COMPARATOR
Intervention: Daily azathioprine 100 mg
Number of subjects: 60
Study: 24040156

Group type: EXPERIMENTAL
Intervention: Educational intervention (one-off group session with DVD, educational booklet, self-monitoring diary, and worksheet)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Educational intervention
Number of subjects: 97

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 97
Study: 21860192

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 180

Group type: COMPARATOR
Intervention: Total Intravenous Anesthesia (TIVA)
Number of subjects: 180
Study: 19318695

Group type: EXPERIMENTAL
Intervention: Intravenous tezosentan at 0.2 mg/h for 24 hours followed by 1.0 mg/h for 24 hours (cohort I)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Intravenous tezosentan at 1.0 mg/h for 24 hours followed by 5.0 mg/h for 24 hours (cohort II)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Intravenous tezosentan (cohort III)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 17349087

Group type: EXPERIMENTAL
Intervention: Rolled oat (O)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Defatted rolled oat (DO)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Rolled whole wheat (W)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Rolled whole wheat with added oat fat (WF)
Number of subjects: 8
Study: 15576069

Group type: EXPERIMENTAL
Intervention: Metyrapone test
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Combined metyrapone/low‐dose dexamethasone test
Number of subjects: 28

Group type: COMPARATOR
Intervention: Visual analogue scale ratings of anxiety, tension, restlessness, and Beck Depression Inventory scores
Number of subjects: 28
Study: 11797027

Group type: COMPARATOR
Intervention: Dopexamine (0.5 microg kg(‐1) min(‐1))
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Dopexamine (1 microg kg(‐1) min(‐1))
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Dopamine (5 microg kg(‐1) min(‐1))
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Dopexamine and dopamine
Number of subjects: 32
Study: 11361908

Group type: EXPERIMENTAL
Intervention: Neuropsychologic testing in asymptomatic HIV-positive children
Number of subjects: 8

Group type: COMPARATOR
Intervention: Seroreverted children
Number of subjects: 8
Study: 8066866

Group type: EXPERIMENTAL
Intervention: n‐3 PUFA capsules (3.6 g)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (six capsules with a fat composition averaging the Danish diet)
Number of subjects: 51
Study: 3167242

Group type: EXPERIMENTAL
Intervention: Male Type A child vignette
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Female Type A child vignette
Number of subjects: 210

Group type: COMPARATOR
Intervention: Male Type B child vignette
Number of subjects: 210

Group type: COMPARATOR
Intervention: Female Type B child vignette
Number of subjects: 210
Study: 662550

Group type: EXPERIMENTAL
Intervention: Field-independent group
Number of subjects: 50

Group type: COMPARATOR
Intervention: Field-dependent group
Number of subjects: 50
Study: 31773211

Group type: EXPERIMENTAL
Intervention: TAK-063
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 30859038

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA 24 U
Number of subjects: 417

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 417
Study: 28982497

Group type: EXPERIMENTAL
Intervention: Aspirin and clopidogrel treatment for one year
Number of subjects: 3602
Study: 25515914

Group type: EXPERIMENTAL
Intervention: Self-regulatory intervention
Number of subjects: 253

Group type: COMPARATOR
Intervention: Standard educational condition
Number of subjects: 253
Study: 23931153

Group type: EXPERIMENTAL
Intervention: Psychosocial screening for perinatal depression, IPV, and substance use problems
Number of subjects: 1868

Group type: COMPARATOR
Intervention: Women of Black, Asian, Pacific Islander, or other race/ethnicity
Number of subjects: 1868

Group type: COMPARATOR
Intervention: Women reporting substance use problems
Number of subjects: 1868

Group type: COMPARATOR
Intervention: Women reporting IPV
Number of subjects: 1868
Study: 22829506

Group type: EXPERIMENTAL
Intervention: Titanium-nitride-oxide-coated bioactive stents (BAS)
Number of subjects: 827

Group type: COMPARATOR
Intervention: Everolimus-eluting stents (EES)
Number of subjects: 827
Study: 20586001

Group type: EXPERIMENTAL
Intervention: Surfactant A
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surfactant B
Number of subjects: 0
Study: 17079060

Group type: EXPERIMENTAL
Intervention: Self-management intervention (The Chronic Disease Self-Management Course, Lorig et al., 2001)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Self-management intervention
Number of subjects: 100
Study: 15738503

Group type: EXPERIMENTAL
Intervention: Escitalopram (10-20 mg)
Number of subjects: 358

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 358
Study: 12197845

Group type: EXPERIMENTAL
Intervention: Baclofen
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 9787686

Group type: EXPERIMENTAL
Intervention: RSV‐IGIV, 750 mg/kg, monthly
Number of subjects: 416

Group type: COMPARATOR
Intervention: Control group (no infusions)
Number of subjects: 416
Study: 7664857

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate, 1 mg daily
Number of subjects: 671

Group type: COMPARATOR
Intervention: Fluticasone propionate, 2 mg daily
Number of subjects: 671

Group type: COMPARATOR
Intervention: Budesonide, 1.6 mg daily
Number of subjects: 671
Study: 2523772

Group type: EXPERIMENTAL
Intervention: nimesulide (100 mg x 2/day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: phenylprenazone (200 mg x 2/day)
Number of subjects: 40
Study: 730841

Group type: EXPERIMENTAL
Intervention: Outreach services
Number of subjects: 7000

Group type: COMPARATOR
Intervention: No outreach services (Control)
Number of subjects: 7000
Study: 31285038

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural intervention delivered by mental health nurse practitioners (MHNPs), consisting of six sessions.
Number of subjects: 198

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 198
Study: 28585163

Group type: EXPERIMENTAL
Intervention: Evidence-based quality improvement (EBQI)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Stakeholder engagement through regional data presentation
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Qualitative interviews with stakeholders
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Inter-professional, multilevel stakeholder engagement
Number of subjects: 87
Study: 26032197

Group type: EXPERIMENTAL
Intervention: Distraction (via a computer game or TV watching)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Attention to eating
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Distraction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Focusing on eating
Number of subjects: 0
Study: 23574691

Group type: EXPERIMENTAL
Intervention: 10-week hatha yoga program, three sessions per week (50 min per session)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 37
Study: 21277410

Group type: EXPERIMENTAL
Intervention: trivalent recombinant hemagglutinin (rHA) vaccine, 45 μg HA/strain
Number of subjects: 601

Group type: COMPARATOR
Intervention: U.S. licensed trivalent inactivated vaccine (TIV), 15 μg HA/strain
Number of subjects: 601

Group type: EXPERIMENTAL
Intervention: Both vaccines
Number of subjects: 601

Group type: EXPERIMENTAL
Intervention: trivalent recombinant hemagglutinin (rHA) vaccine
Number of subjects: 601
Study: 18077012

Group type: COMPARATOR
Intervention: 0.5 g Vit-C/day
Number of subjects: 36

Group type: COMPARATOR
Intervention: 1 g Vit-C/day
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 36
Study: 16452740

Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate (1 mL of 10 mg/mL)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline solution (1 mL of phosphate-buffered saline)
Number of subjects: 20
Study: 15043521

Group type: EXPERIMENTAL
Intervention: Motilin (4 pmol.min/kg)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 11043126

Group type: EXPERIMENTAL
Intervention: Autologous chondrocyte transplantation (ACT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Osteochondral cylinder transplantation (OCT)
Number of subjects: 20
Study: 9280177

Group type: EXPERIMENTAL
Intervention: Soluble fiber diet
Number of subjects: 33
Study: 8320622

Group type: EXPERIMENTAL
Intervention: Soy protein diet for 8 weeks
Number of subjects: 23

Group type: COMPARATOR
Intervention: Standard low fat, low cholesterol diet
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Standard low fat, low cholesterol diet after 8 weeks of soy protein diet
Number of subjects: 23

Group type: COMPARATOR
Intervention: Soy protein diet after 8 weeks of standard low fat, low cholesterol diet
Number of subjects: 23
Study: 3548603

Group type: EXPERIMENTAL
Intervention: Contingent alarm device
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Non-contingent alarm device
Number of subjects: 44

Group type: COMPARATOR
Intervention: Both alarm devices
Number of subjects: 44
Study: 31512487

Group type: EXPERIMENTAL
Intervention: Higher consumption of beans, grains, milk, fruits, and vegetables
Number of subjects: 3397

Group type: EXPERIMENTAL
Intervention: Higher consumption of eggs and potatoes
Number of subjects: 3397

Group type: EXPERIMENTAL
Intervention: Higher levels of vitamin D, chloride, total serum protein, and red blood cell folate
Number of subjects: 3397

Group type: EXPERIMENTAL
Intervention: Higher levels of C‐reactive protein and vitamin B12
Number of subjects: 3397
Study: 30348219

Group type: EXPERIMENTAL
Intervention: Health facility delivery
Number of subjects: 309

Group type: COMPARATOR
Intervention: Home delivery
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Joint decision-making with husbands
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Husbands choose health facility delivery
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Medium wealth status
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Access to health facility within 2 km
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Traditional means of transport
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Reading newspapers daily or infrequently
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Knowledge about complications during delivery
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Good perception on quality of care received
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Previous facility delivery
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Negative experiences of delivery outcomes in community
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Perception of home delivery as life threatening
Number of subjects: 309
Study: 27665206

Group type: EXPERIMENTAL
Intervention: Vitamin K antagonist treatment (e.g., warfarin)
Number of subjects: 2718

Group type: COMPARATOR
Intervention: Women
Number of subjects: 2718

Group type: COMPARATOR
Intervention: Black race
Number of subjects: 2718

Group type: COMPARATOR
Intervention: New York Heart Association class IV
Number of subjects: 2718

Group type: EXPERIMENTAL
Intervention: Hemoglobin >13.5 g/dl
Number of subjects: 2718

Group type: EXPERIMENTAL
Intervention: New York Heart Association class I
Number of subjects: 2718

Group type: COMPARATOR
Intervention: US sites
Number of subjects: 2718

Group type: COMPARATOR
Intervention: SAMe‐TT2R2 scores of 4 or higher
Number of subjects: 2718

Group type: COMPARATOR
Intervention: SAMe‐TT2R2 scores of 1
Number of subjects: 2718

Group type: EXPERIMENTAL
Intervention: Lower SAMe‐TT2R2 score
Number of subjects: 2718
Study: 24642648

Group type: EXPERIMENTAL
Intervention: Vaginal lactoferrin (LF) 300 mg administered 4 hours before amniocentesis
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Vaginal lactoferrin (LF) 300 mg administered 12 hours before amniocentesis
Number of subjects: 60

Group type: COMPARATOR
Intervention: Untreated patients (control group)
Number of subjects: 60
Study: 22372573

Group type: EXPERIMENTAL
Intervention: Tailored multi-faceted improvement programme
Number of subjects: 119

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 119
Study: 19616895

Group type: EXPERIMENTAL
Intervention: 10mg of hydrocortisone
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Number of subjects: 32
Study: 18622175

Group type: EXPERIMENTAL
Intervention: Alcohol (0.6 g/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16267768

Group type: EXPERIMENTAL
Intervention: Single-dose sulfadoxine-pyrimethamine (S-P)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 11867042

Group type: EXPERIMENTAL
Intervention: losartan 50 mg/day
Number of subjects: 18

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 18
Study: 10190768

Group type: EXPERIMENTAL
Intervention: Decreased carbohydrate condition (39.4% CHO)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Increased carbohydrate condition (59.2% CHO)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Normal mixed diet (53.6% CHO)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Normal diet (52.7% CHO)
Number of subjects: 15
Study: 7756640

Group type: EXPERIMENTAL
Intervention: Antithymocyte globulin (ATG) and cyclosporine (CsA) administered simultaneously for 4 days and 6 months respectively
Number of subjects: 55
Study: 2147837

Group type: EXPERIMENTAL
Intervention: Dobutamine (5 to 10 micrograms/Kg/mn)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Enoximone (1 mg/kg bolus followed by intravenous infusion of 5 to 10 micrograms/Kg/mn)
Number of subjects: 40
Study: 6768081

Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 0
Study: 31612653

Group type: EXPERIMENTAL
Intervention: Botox
Number of subjects: 24

Group type: COMPARATOR
Intervention: Neuronox
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both Botox and Neuronox
Number of subjects: 24
Study: 29037641

Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative treatment (OMT)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Sham therapy (SG)
Number of subjects: 31
Study: 26527536

Group type: EXPERIMENTAL
Intervention: Aqueous extract of noble kava cultivar (standardised to 240 mg of kavalactones per day)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 210
Study: 23098762

Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA 100 U
Number of subjects: 563

Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA 200 U
Number of subjects: 563

Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA 300 U
Number of subjects: 563

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 563

Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA (all doses)
Number of subjects: 563
Study: 22045820

Group type: EXPERIMENTAL
Intervention: Direct mailing of faecal occult blood tests (FOBT)
Number of subjects: 7415

Group type: COMPARATOR
Intervention: Standard invitation
Number of subjects: 7415
Study: 19370699

Group type: EXPERIMENTAL
Intervention: Moderate smoking trajectory (74.6% of participants)
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Heavy smoking trajectory (remaining participants)
Number of subjects: 268
Study: 16150010

Group type: EXPERIMENTAL
Intervention: Emotion‐cognition focused program
Number of subjects: 96
Study: 12575787

Group type: EXPERIMENTAL
Intervention: Fibrin sealant (2-5 cm3)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control (no fibrin sealant)
Number of subjects: 55
Study: 10571630

Group type: EXPERIMENTAL
Intervention: 2% lignocaine hydrochloride gel at 4 degrees C
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 2% lignocaine hydrochloride gel at 40 degrees C
Number of subjects: 60

Group type: COMPARATOR
Intervention: 2% lignocaine hydrochloride gel at 22 degrees C (control group)
Number of subjects: 60
Study: 8729491

Group type: EXPERIMENTAL
Intervention: Client centred hypnotherapy (CCH)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Counselling
Number of subjects: 86
Study: 1899079

Group type: EXPERIMENTAL
Intervention: Buserelin 1200 micrograms/day intranasally (n = 22)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Immediate surgery (n = 20)
Number of subjects: 42
Study: 6352001

Group type: EXPERIMENTAL
Intervention: Initial therapy directed at the poor-prognosis component of tumors
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Further biopsy at the time of relapse
Number of subjects: 323
Study: 31805968

Group type: EXPERIMENTAL
Intervention: Implementation toolkit (arm 1)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Toolkit + in-person training + training webinars (arm 2)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Toolkit + training + webinars + offered practice facilitation (arm 3)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Non-study CHCs
Number of subjects: 29
Study: 28767271

Group type: EXPERIMENTAL
Intervention: TEAS plus exercise therapy (TG)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Sham TEAS plus exercise therapy (CG)
Number of subjects: 23
Study: 26814294

Group type: EXPERIMENTAL
Intervention: ABT-639 (100 mg)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Pregabalin (300 mg)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 24952366

Group type: EXPERIMENTAL
Intervention: Prospective care pathway
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: BMI 30‐39.9 kg/m²
Number of subjects: 105

Group type: COMPARATOR
Intervention: BMI >40 kg/m²
Number of subjects: 105
Study: 22377591

Group type: EXPERIMENTAL
Intervention: Counseling for prevention of weight gain
Number of subjects: 40

Group type: COMPARATOR
Intervention: Dietary intakes of n3 fatty acids, BMI, serum levels of carotenoids, TV hours watched/day
Number of subjects: 40
Study: 19583074

Group type: EXPERIMENTAL
Intervention: EMLA cream
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Placebo cream
Number of subjects: 60
Study: 17421001

Group type: EXPERIMENTAL
Intervention: Whole-saliva collection device (Oragene DNA collection kit)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Oral rinse
Number of subjects: 17

Group type: COMPARATOR
Intervention: Foam swab
Number of subjects: 17

Group type: COMPARATOR
Intervention: Cytobrush
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Whole-saliva and oral-rinse samples
Number of subjects: 17
Study: 15791633

Group type: EXPERIMENTAL
Intervention: Pelvic Floor Muscle Training (PFMT) for 12 weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control Group (no intervention)
Number of subjects: 24
Study: 12784700

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 9862579

Group type: EXPERIMENTAL
Intervention: Chromosome 5 allelic losses (LOH) in ampullary tumours
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Chromosome 5 LOH in adenomas
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Chromosome 5 LOH in early-stage cancers
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Chromosome 5 LOH in advanced-stage cancers
Number of subjects: 27
Study: 7896982

Group type: EXPERIMENTAL
Intervention: Brief psychodynamic-interpersonal treatment
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment
Number of subjects: 39
Study: 1698333

Group type: EXPERIMENTAL
Intervention: Early diet program for preterm infants
Number of subjects: 0
Study: 582549

Group type: EXPERIMENTAL
Intervention: Lithium medication (dosage: 24 mval/d to 36 mval/d)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 30674311

Group type: EXPERIMENTAL
Intervention: PACIC‐5A questionnaire
Number of subjects: 117
Study: 28397569

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (FLU‐IVIG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Misclassification and collapsing categories
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Collapsing categories with no treatment effect
Number of subjects: 0